AU2020219112A1 - Connexin 43 antibodies and use thereof - Google Patents

Connexin 43 antibodies and use thereof Download PDF

Info

Publication number
AU2020219112A1
AU2020219112A1 AU2020219112A AU2020219112A AU2020219112A1 AU 2020219112 A1 AU2020219112 A1 AU 2020219112A1 AU 2020219112 A AU2020219112 A AU 2020219112A AU 2020219112 A AU2020219112 A AU 2020219112A AU 2020219112 A1 AU2020219112 A1 AU 2020219112A1
Authority
AU
Australia
Prior art keywords
antibody
fragment
seq
antibodies
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020219112A
Other languages
English (en)
Inventor
Yanfeng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alamab Therapeutics Inc
Original Assignee
Alamab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alamab Therapeutics Inc filed Critical Alamab Therapeutics Inc
Publication of AU2020219112A1 publication Critical patent/AU2020219112A1/en
Priority to AU2022218583A priority Critical patent/AU2022218583B9/en
Priority to AU2026201299A priority patent/AU2026201299A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Computer And Data Communications (AREA)
AU2020219112A 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof Abandoned AU2020219112A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022218583A AU2022218583B9 (en) 2019-02-04 2022-08-18 Connexin 43 Antibodies And Use Thereof
AU2026201299A AU2026201299A1 (en) 2019-02-04 2026-02-20 Connexin 43 Antibodies And Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800869P 2019-02-04 2019-02-04
US62/800,869 2019-02-04
PCT/US2020/016606 WO2020163353A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022218583A Division AU2022218583B9 (en) 2019-02-04 2022-08-18 Connexin 43 Antibodies And Use Thereof

Publications (1)

Publication Number Publication Date
AU2020219112A1 true AU2020219112A1 (en) 2021-08-26

Family

ID=71947290

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2020219112A Abandoned AU2020219112A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof
AU2022218583A Active AU2022218583B9 (en) 2019-02-04 2022-08-18 Connexin 43 Antibodies And Use Thereof
AU2026201299A Pending AU2026201299A1 (en) 2019-02-04 2026-02-20 Connexin 43 Antibodies And Use Thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022218583A Active AU2022218583B9 (en) 2019-02-04 2022-08-18 Connexin 43 Antibodies And Use Thereof
AU2026201299A Pending AU2026201299A1 (en) 2019-02-04 2026-02-20 Connexin 43 Antibodies And Use Thereof

Country Status (9)

Country Link
US (2) US12187794B2 (https=)
EP (1) EP3920969A4 (https=)
JP (2) JP7709917B2 (https=)
KR (1) KR20210153039A (https=)
CN (2) CN119700967A (https=)
AU (3) AU2020219112A1 (https=)
CA (1) CA3128987A1 (https=)
IL (2) IL320816A (https=)
WO (1) WO2020163353A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095897A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
US6745478B2 (en) 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
KR102073629B1 (ko) * 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
MX2010012324A (es) * 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
US20110223204A1 (en) * 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
CA2823154A1 (en) * 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
CN114621346B (zh) * 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
CN107109410B (zh) * 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
CA3095897A1 (en) * 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Also Published As

Publication number Publication date
IL320816A (en) 2025-07-01
CN119700967A (zh) 2025-03-28
JP2025090679A (ja) 2025-06-17
JP7709917B2 (ja) 2025-07-17
CN112384244A (zh) 2021-02-19
IL285369B2 (en) 2025-10-01
EP3920969A1 (en) 2021-12-15
US20250230233A1 (en) 2025-07-17
JP2022519293A (ja) 2022-03-22
CA3128987A1 (en) 2020-08-13
CN112384244B (zh) 2025-01-24
US20220411494A1 (en) 2022-12-29
IL285369B1 (en) 2025-06-01
AU2022218583A1 (en) 2022-10-06
WO2020163353A1 (en) 2020-08-13
AU2022218583B9 (en) 2025-12-04
US12187794B2 (en) 2025-01-07
EP3920969A4 (en) 2022-11-30
KR20210153039A (ko) 2021-12-16
IL285369A (en) 2021-09-30
AU2026201299A1 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
US20250289876A1 (en) Connexin 43 antibodies and use thereof
US20250230233A1 (en) Connexin 43 antibodies and use thereof
CN111704672B (zh) 抗血浆激肽释放酶抗体
CN112955548B (zh) 叶酸受体α特异性抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
HK40043616A (en) Connexin 43 antibodies and use thereof
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
HK40043616B (zh) 连接蛋白43抗体及其用途
HK40100613A (zh) 连接蛋白43抗体及其用途
HK40042791A (en) Connexin 43 antibodies and use thereof
TW202515906A (zh) 治療中風之方法
NZ618046B2 (en) Fc RECEPTOR BINDING PROTEINS
NZ618046A (en) Fc receptor binding proteins

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted